ArticleDysphagia2026
Development and Validation of a Clinical Risk Score for Post-extubation Dysphagia (CRISPED) in Critically Ill Children.
Article in Dysphagia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Characteristics, predictors, and management of post-extubation dysphagia in critically Ill children: a scoping review.Frontiers in pediatrics · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to develop and validate a clinical risk score (CRISPED) for predicting post-extubation dysphagia (PED) in critically ill children. We conducted a prospective cohort study in a pediatric intensive care unit of a tertiary hospital (2021-2025). Consecutive children aged 1 month to 15 years requiring invasive mechanical ventilation ≥ 24 h were eligible. PED was defined as Functional Oral Intake Scale < 6 at first post-extubation speech-language pathology (SLP) assessment. The candidate predictors were evaluated using LASSO logistic regression. The cohort was split into development (n = 300) and validation (n = 132) samples for model assessment. Overall, the PED incidence was 65% among 432 patients included in the study. Three independent predictors were retained: iatrogenic withdrawal syndrome, number of intubations, and intubation duration. The CRISPED score demonstrated strong discrimination in the development cohort (C-statistic 0.85, 95% CI 0.80-0.89; accuracy 75%; Brier score 0.14) with good calibration (Hosmer-Lemeshow p = 0.44). Bootstrap internal validation confirmed minimal optimism with corrected C-statistic 0.84. Performance remained robust in the validation cohort (C-statistic 0.86, 95% CI 0.79-0.92; accuracy 80%; Brier score 0.15). Risk stratification into low (≤ 13 points), intermediate (14-17), and high (≥ 18) categories showed progressive PED prevalence: 21.8%, 61.5%, and 87.5% (p < 0.001). For severe PED (tube dependent patients), discrimination remained good (C-statistic 0.80; accuracy 75.8%). The CRISPED score provides accurate risk stratification for PED using three readily available clinical variables. It enables early identification of high-risk patients for prioritized SLP interventions, potentially improving clinical outcomes. External multicenter validation is essential before widespread clinical implementation.
Indexed as
Identifiers
41627395What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.